You do not have permission to access this chart.
Please Sign Up or Login

Surface Oncology, Inc., a clinical-stage immuno-oncology company, engages in the development of cancer therapies in the United States. The company develops various antibodies that include NZV930, a fully human immunoglobulin isotype G4 (IgG4) monoclonal antibody for the production of extracellular adenosine; SRF617, a fully human IgG4 monoclonal antibody that inhibits CD39 enzymatic activity for the production of adenosine and the breakdown of adenosine triphosphate; SRF388 targeting interleukin 27; SRF813 targeting CD112R, an inhibitory protein expressed on natural killer and T cells; and SRF114 targeting the chemokine receptor CCR8 to deplete immuno-suppressive cells. It also develops an earlier stage program targeting regulatory T cells. The company has a strategic collaboration agreement with Novartis Institutes for Biomedical Research, Inc. for the development of cancer therapies; and a license agreement with GlaxoSmithKline to develop, manufacture, and commercialize antibodies that targets SRF813. Surface Oncology, Inc. was incorporated in 2014 and is headquartered in Cambridge, Massachusetts.

Sector:

Healthcare

Industry:

Biotechnology

Employees:

51

Address:

Surface Oncology, Inc. 50 Hampshire Street 8th Floor Cambridge MA 02139 United States

Website:

http://www.surfaceoncology.com

Phone:

617-714-4096

Leave a comment

Your email address will not be published. Required fields are marked *